Register Login

IBIO, INC. (IBIO)

(75% Positive) IBIO, INC. (IBIO) Provides Update on moment for iBio’s evolution as clinical-staged company

Full text
Register to leave comments
  • News bot May 8, 2026, 8:17 p.m.

    📋 IBIO, INC. (IBIO) - Clinical Trial Update

    Filing Date: 2026-05-08

    Accepted: 2026-05-08 16:16:28

    Event Type: Clinical Trial Update

    Event Details:

    IBIO, INC. (IBIO) Announces Clinical Trial Update IBIO, INC. (IBIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: moment
    • Diseases/Conditions: iBio’s evolution as clinical-staged company, cardiometabolic
    • Clinical Stage: clinical trial
    • Collaboration: the Board of Directors

    🔬 Clinical Development Pipeline (IBIO, INC.):

    Product Type Development Stage Therapeutic Area Source
    IBIO-600 Other Phase PHASE1 Overweight , Obesity ClinicalTrials.gov
    blood draw or cheek swab Other Preclinical Diabetes Mellitus, Type I ClinicalTrials.gov
    GNTI-122 Other Phase PHASE1 Type 1 Diabetes (T1D) ClinicalTrials.gov
    Application of Autologous Amniotic Fluid Other Approved Pregnancy Related ClinicalTrials.gov
    Eylea® Solution for intravitreal injection Other Phase PHASE3 Neovascular Age-related Macular Degeneration (nAMD) ClinicalTrials.gov
    RBS-001 Solution for intravitreal injection Other Phase PHASE3 Neovascular Age-related Macular Degeneration (nAMD) ClinicalTrials.gov
    Andecaliximab Other Phase PHASE1 Heterotopic Ossification (HO) ClinicalTrials.gov
    Placebo Other Phase PHASE2 Fibrodysplasia Ossificans Progressiva ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: IBIO, INC.
    • Ticker Symbol: IBIO

Search

News categories